INS and type 2 diabetes mellitus: Efsitora alfa has shown consistent glycaemic control across a broad range of patient populations with type 2 diabetes—from insulin-naïve individuals (QWINT-1, QWINT-2) to those previously treated with basal or basal-bolus insulin (QWINT-3, QWINT-4).